VEGF inhibitor (monoclonal antibody)

This page covers all VEGF inhibitor (monoclonal antibody) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF (Vascular Endothelial Growth Factor), VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component), VEGF-A, VEGF-B, PlGF (placental growth factor).

Targets

VEGF (Vascular Endothelial Growth Factor) · VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component) · VEGF-A, VEGF-B, PlGF (placental growth factor) · VEGF-A · VEGF-A, VEGF-B, PlGF (Placental Growth Factor) · VEGF (vascular endothelial growth factor) · VEGF-A (Vascular Endothelial Growth Factor A) · VEGF165 (vascular endothelial growth factor) · VEGF165 (Vascular Endothelial Growth Factor) · VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors

Marketed (22)

• Subconjunctival Bevacizumab · Grewal Eye Institute · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
• Bevacizumab-awwb · Amgen · Oncology
  Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
• aflibercept + FOLFIRI · CR-CSSS Champlain-Charles-Le Moyne · Oncology
  Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.
• Aflibercept Intravitreous Injection · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye.
• Intravitreal bevacizumab · University of Sao Paulo · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• Bevacizumab (Avastin®) · Hanny Al-Samkari, MD · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow.
• Rescue Intravitreal Aflibercept Injection · Southeast Retina Center, Georgia · Ophthalmology
  Aflibercept is a recombinant fusion protein that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the retina.
• Lucentis (Treat and extend) · Retinal Consultants of Arizona · Ophthalmology
  Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.
• Intravitreal Bevacizumab IVB · Khyber Teaching Hospital · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• Ziv aflibercept · Marashi Eye Clinic · Ophthalmology
  Ziv-aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor, binding and sequestering vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization.
• Aflibercept (Eylea) · Ahmad Zeeshan Jamil · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling.
• Aflibercept Injection [Eylea] · Caregen Co. Ltd. · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.
• Intravitreal injection of bevacizumab · Barnes Retina Institute · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
• intravitreal ranibizumab injections · Hospital Regional de São José - Dr. Homero de Miranda Gomes · Ophthalmology
  Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
• pegaptanib sodium injection · Bausch & Lomb Incorporated · Ophthalmology
  Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
• Bevacizumab (Bev) · Eli Lilly and Company · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Macugen (Pegaptanib Sodium) · Retina Institute of Hawaii · Ophthalmology
  Pegaptanib is an aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
• anti-VEGF agent · Medical University of Vienna · Oncology, Ophthalmology
  Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis.
• Ranibizumab and laser · Fukushima Medical University · Ophthalmology
  Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue.
• intravitreal injection with ranibizumab · University Hospital Muenster · Ophthalmology
  Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
• Intravitreal Aflibercept Injection · Ophthalmic Consultants of Boston · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye.
• intravitreal Anti-VEGF injection · Seoul National University Bundang Hospital · Ophthalmology
  Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.

Phase 3 pipeline (48)

• Aflibercept-mFOLFIRI3 · Hôpital Franco-Britannique-Fondation Cognacq-Jay · Oncology
  Aflibercept-mFOLFIRI3 is a combination regimen that pairs aflibercept (a VEGF trap) with modified FOLFIRI chemotherapy to inhibit angiogenesis while delivering cytotoxic chemotherapy.
• Ranibizumab injection and TTT - ICG based · New England Retina Associates · Ophthalmology
  Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth in the retina, combined with transpupillary thermotherapy (TTT) using indocyanine green (ICG) guidance for targeted thermal ablation.
• Ranibizumab + laser · Jaeb Center for Health Research · Ophthalmology
  Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina.
• HLX04-O · Shanghai Henlius Biotech · Oncology
  HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• HLX04, a bevacizumab biosimilar · Shanghai Henlius Biotech · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab · Lee's Pharmaceutical Limited · Oncology
  Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.
• Bevacizumab as Avastin · Mylan Pharmaceuticals Inc · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• EU Avastin® · Bio-Thera Solutions · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation and slow cancer growth.
• Ramucirumab DP (IMC-1121B) · Eli Lilly and Company · Oncology
  Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
• CT-P51 · Celltrion · Oncology
  CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• QL1101 · Qilu Pharmaceutical Co., Ltd. · Oncology
  QL1101 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• bevacizumab, erlotinib · Swiss Cancer Institute · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
• Aflibercept (Regeneron, USA) · Cinnagen · Oncology, Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.
• Eylea HD (aflibercept HD) · Alvotech Swiss AG · Ophthalmology
  Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.
• Subconjunctival Avastin · Vanak Eye Surgery Center · Ophthalmology
  Avastin (bevacizumab) inhibits vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel formation and leakage in the eye.
• Prompt aflibercept · Jaeb Center for Health Research · Oncology, Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis.
• VEGF Trap-Eye (BAY86-5321) · Bayer · Ophthalmology
  VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye.
• Atezolizumab & Bevacizumab · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Oncology
  Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.
• Eylea® Solution for intravitreal injection · Rophibio, Inc. · Ophthalmology
  Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.
• ABP 206 · Amgen · Oncology
  ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevacizumab-Pfizer · Pfizer · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• Deferred aflibercept · Jaeb Center for Health Research · Ophthalmology / Oncology
  Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors.
• OCS-01 · Oculis · Ophthalmology
  OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.
• Bevacizumab control · Institut de Recherches Internationales Servier · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
• HR17031 injection · Jiangsu HengRui Medicine Co., Ltd. · Oncology
  HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.
• Gentuximab Injection · Changchun GeneScience Pharmaceutical Co., Ltd. · Oncology
  Gentuximab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and blood vessel formation.
• Placebo to bevacizumab · Hoffmann-La Roche · Oncology
  Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.
• Intralesional injection of bevacizumab · Khon Kaen University · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply.
• SB8 · Samsung Bioepis Co., Ltd. · Oncology
  SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevacizumab as MYL-1402O · Mylan Pharmaceuticals Inc · Oncology
  MYL-1402O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• HLX04 · Shanghai Henlius Biotech · Oncology
  HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.
• MYL-1701P, a proposed biosimilar to Eylea · Mylan Pharmaceuticals Inc · Ophthalmology
  MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
• China-approved Bevacizumab · Zhejiang Teruisi Pharmaceutical Inc. · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
• EU-sourced Avastin® · Cipla BioTec Pvt. Ltd. · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• AVT04 · Alvotech Swiss AG · Oncology
  AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Bevazizumab intravitreal injection · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Ophthalmology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
• Avastin intravitreal injection · Ophthalmological Association Edelweiss · Ophthalmology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
• Bevacizumab + Deferred Aflibercept Group · Jaeb Center for Health Research · Oncology
  This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.
• FKB238 (bevacizumab) · Centus Biotherapeutics Limited · Oncology
  FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• miFL + bevacizumab · Pfizer · Oncology
  miFL is a monoclonal antibody that targets bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor.

Phase 2 pipeline (5)

• Aflibercept intravitreal injection · Innostellar Biotherapeutics Co.,Ltd · Ophthalmology
  Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.
• Bevacizumab and FOLFIRI · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.
• Aatezolizumab plus Bevacizumab · Tae Won Kim · Oncology
  Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.
• Capecitabine and Bevacizumab · South Eastern European Research Oncology Group · Oncology
  Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.
• Intravitreal injection of KH902 · Chengdu Kanghong Biotech Co., Ltd. · Ophthalmology
  KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

Phase 1 pipeline (1)

• AAV2-sFLT01 · Genzyme, a Sanofi Company · Oncology
  VEGF inhibitor

Patent intelligence

• vegf inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates